Caris Life Sciences
138 hedge funds and large institutions have $3.41B invested in Caris Life Sciences in 2025 Q3 according to their latest regulatory filings, with 53 funds opening new positions, 45 increasing their positions, 19 reducing their positions, and 31 closing their positions.
649% more call options, than puts
Call options by funds: $12.3M | Put options by funds: $1.65M
137% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 19
71% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 31
19% more funds holding
Funds holding: 116 → 138 (+22)
17% more capital invested
Capital invested by funds: $2.92B → $3.41B (+$488M)
1.77% more ownership
Funds ownership: 38.56% → 40.33% (+1.8%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
PointState Capital
New York
|
+$44.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.9M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$27.1M |
| 4 |
Morgan Stanley
New York
|
+$23.3M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$23.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
-$60.4M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$26.7M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$16.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$10.9M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$9.89M |
CAI Hedge Fund Activity: Q3 2025 in Review
138 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Caris Life Sciences (CAI) for Q3 2025, worth a combined $3.41B — up 17% from $2.92B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new CAI positions and 31 closed out — a net gain of 22 holders — while 45 added to existing stakes and 19 trimmed.
The largest buyer was PointState Capital, adding an estimated $44.2M. The largest seller was Neuberger Berman Group, cutting an estimated $60.4M.
- 138 institutional investors held Caris Life Sciences (CAI) as of Q3 2025, up from 116 in Q2 2025.
- Funds reported $3.41B of Caris Life Sciences stock for Q3 2025, up 17% quarter-over-quarter.
- 53 funds opened new Caris Life Sciences positions in Q3 2025 and 31 closed out, a net change of +22 holders.
- The largest Caris Life Sciences buyer in Q3 2025 was PointState Capital, an estimated $44.2M added.
- The largest Caris Life Sciences seller in Q3 2025 was Neuberger Berman Group, an estimated $60.4M sold.
Based on aggregated 13F filings for Q3 2025.